Project RETAIN: Providing Integrated Care for HIV-Infected Crack Cocaine Users
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- HIV
- Sponsor
- Columbia University
- Enrollment
- 360
- Locations
- 2
- Primary Endpoint
- Virologic suppression
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
This study will evaluate the efficacy of an integrated "Retention Clinic" in achieving virologic suppression among HIV-infected cocaine (including crack) users by using a two-group randomized, prospective trial. A total of 360 HIV-infected individuals who report cocaine (including crack) use will be randomized across study sites. The primary hypothesis is that more participants randomized to the "Retention Clinic" will have undetectable viral load than will participants randomized to the treatment as usual group.
Detailed Description
This study will evaluate the efficacy of an integrated "Retention Clinic" in achieving virologic suppression among HIV-infected cocaine (including crack) users by using a two-group randomized, prospective trial. Participants will be randomized to one of two groups: 1) "Retention Clinic" group and 2) Treatment as Usual. The intervention content of these groups is briefly described below: Retention Clinic (RC) Group: This group will receive comprehensive and integrated services from a Retention Clinic. Services include HIV primary care, substance abuse treatment and mental health services, as needed. Participants in this group will also receive hands-on assistance with navigating through the clinic and accessing these services from a patient navigator. Treatment as Usual (TAU) Group: This group will receive no protocol directed intervention. They will get the standard retention services from their local clinic. All participants will provide informed consent and will complete a baseline audio computer-assisted self-interview or ACASI focusing on drug use, mental health, demographics and socio-economic factors, HIV care, and drug treatment history as well as blood draws for viral load and CD4 count. Follow-up assessments consisting of both ACASI and blood draws in all groups will be collected at 6 and 12 months post-randomization. Medical records will be reviewed to document use of HIV care, drug treatment and mental health services during the study period.
Investigators
Lisa Metsch
Stephen Smith Professor and Chair of Sociomedical Sciences Department
Columbia University
Eligibility Criteria
Inclusion Criteria
- •Participating individuals must:
- •be at least 18 years old
- •be HIV-seropositive (confirmed via medical record/laboratory results or via rapid HIV test in conjunction with confirmatory test or viral load)
- •meet one of the following: a) have an (\*)AIDS-defining illness OR b) have a CD4 count \<350 cells/uL AND a viral load \>1000 copies/mL in the medical record in the past 3 months OR c) have a CD4 count \<350 cells/uL AND a viral load \>200 copies/mL as obtained via baseline blood draw OR d) have a clinical profile indicative of a persistently detectable HIV viral load (\>200 copies/mL) attributed to non-adherence to HIV medications as per PI evaluation of the individual and/or individual's medical record
- •report (OR have evidence in the medical record of) any cocaine (including crack) use in the past 3 months OR (\*\*)have a positive toxicology result for cocaine via the study toxicology screen
- •agree to have their blood drawn for CD4 and viral load testing
- •report living in or near either Miami, Florida (FL), or Atlanta, Georgia (GA), and be able to return for follow-up visits
- •provide locator information
- •be able to communicate in English
- •provide written informed consent
Exclusion Criteria
- •Individuals will be excluded from study participation if they:
- •do not meet any one or more of the above-described inclusion criteria
- •are receiving patient navigator services for HIV care and/or substance abuse treatment
- •have significant cognitive or developmental impairment to the extent that they are unable to provide informed consent
- •are terminated via site PI decision
Outcomes
Primary Outcomes
Virologic suppression
Time Frame: 12 months
To evaluate the effectiveness of the integrated "Retention Clinic" in achieving virologic suppression (defined as having an HIV-1 viral load \<200 copies/mL at 6 and 12 months) among HIV-infected cocaine (including crack) users
Secondary Outcomes
- Attendance to HIV Care Visits(12 months)
- Adherence to HIV Treatment Regimens(12 months)
- Attendance to Substance Abuse Treatment(12 months)
- Decreasing Substance Use(12 months)